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Objective: To evaluate the efficacy and safety of oromucosal low-dose human lymphoblastoid interferon alpha (IFN- 
a-n1 [INS]) following steroid withdrawal in Filipino patients with chronic replicative hepatitis B virus (HBV) infection. 
Study design: Randomized, double blind, placebo-controlled trial on IFN-a-n1 [INS], two tablets of 200 IU each or 
placebo, given sublingually once daily for eight months following steroid or placebo priming and withdrawal. 
Results: A statistically significant clearance of hepatitis B e antigen (HBeAg) (50%) an seroconversion to positive d 
antibody to HBeAg (anti-HBe) (42.9%) was noted in those given IFN-a-n1 [INS] compared with the placebo group. 
Clearance of serum HBV-DNA was not significantly different and none cleared HBsAg in both groups. More 
patients (57%) had normalization of ALT on IFN-a-n1 [INS] compared with controls (31.3%). Oromucosal IFN-a- 
nl [INS] was devoid of any evidence of toxicity. 
Conclusion: This study conducted on a limited number of patients demonstrates the potential efficacy of oromucosal 
IFN-a-n1 [INS] in chronic HBV infection with therapeutic benefit equal to parenterally administered interferon 
alpha (IFNa) but without the side effects of myelosuppresion. Owing to the small population studied, we are unable 
to extrapolate these findings to the general population of patients with chronic HBV infection. A large-scale study 
is needed to confirm these findings. 
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Interferon alpha (IFN-a) has been the standard 
treatment of chronic HBV infection in most countries.’ 
The response to interferon among Asian patients 
has been poorer compared with Caucasians.2J Steroid 
priming and withdrawal preceding IFN-a has been 
reported to enhance the efficacy of IFN-a and the 
cumulative sustained response on long-term follow up 
among Chinese patients was significantly higher 
compared to those on IFN-a alone.4*5 
Parenterally administered IFN(a) is associated 
with significant dose related side effects6 In contrast, 
oromucosal low-dose human lymphoblastoid interferon 
alpha (IFN-a-n1 [INS]) has been reported to have no 
associated adverse effect.7Ts 
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This randomized, double blind, placebo-controlled 
trial was undertaken to determine the efficacy and 
safety of oromucosal low-dose human lymphoblastoid 
interferon alpha (IFN-a- nl [INS]) following prednisone 
withdrawal in Filipino patients with chronic HBV 
infection. 
PATIENTS AND METHODS 
The estimated sample size of 44 (22 allocated per 
treatment arm) would have a power of 0.8, at a 95% 
confidence level, to detect a statistically significant differ- 
ence between a response rate of 40% in the treatment 
arm, assuming a 7% spontaneous clearance of HBeAg 
in the placebo control arm. 
Patients with chronic replicative HBV infection 
with alanine aminotransferase (ALT) at least >1.5 of 
the upper limit of normal were randomly allocated into 
each arm after written informed consent. Excluded were 
patients who were positive for HIV, hepatitis C virus, 
hepatitis delta antibody, or those with evidence of 
decompensated liver disease, elevated alpha fetoprotein 
or any serious psychiatric or medical condition. 
The patients were primed with two capsules of 
prednisone, 5 mg/capsule, or matching placebo capsules, 
thrice daily for three weeks, then one capsule thrice 
daily during the fourth week.Two weeks after steroid or 
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Table 1. Demographic and baseline data on patients randomized to INF-u-n1 or placebo and in patients who were compared to 
those who were not able to be evaluated in either treatment arm. No statistically significant differences in sociodemographic and 
baseline parameters were noted between the patients randomized to IFN-a-n1 [INS] and placebo, those who could and could not be 
evaluated in each treatment arm, and between those who could be evaluated in both treatment arms 
Demographics 
Number 
% Females 
Mean age (yrs) 
Median Age 
Randomization IFN-d-n 1 (INS) Placebo 
IFN-a-n I Placebo Evaluable lnevaluable Evaluable lnevaluable 
(INS) 17 19 14 3 16 3 
23.5 10.5 28.6 0 12.5 16.6 
29.0+9.0 30.0+10.2 27.0+6.1 39.0+14.4 29.0+9.3 34.0+16.2 
27 27 25 35 27 26 
Mean HBV- DNA* 140.3+164.2 154.1+179.2 114.5+164.5 252.4+129.0 169.5+185.2 38.7+54.7 
Mean ALT level** 145.2+54.9 124.5+45.5 148.0+57.9 132.0+45.6 118.8+37.6 155.3+74.7 
cl00 IU/ml 5 (29.4)x** 8 (42.1) 4 (28.6) 1 (33.3) 7 (43.8) 1 (33.3) 
2100 IUlml 12(70.6) 11 (57.9) 10 (71.4) 2 (66.7) 9 (56.2) 2 (66.7) 
*pg/ml, **W/ml, ***No (%) 
placebo withdrawal, the patients were given two tablets 
once daily of 200 IU IFN-a-n1 [INS] or identical placebo 
tablets sublingually until they were completely dis- 
solved, allowing nothing by mouth for 30 minutes before 
and after the medication. 
HBsAg, HbeAg, and antiHBe by radioimmuno- 
assay or enzyme-linked immunoassay (ELISA), and 
HBV-DNA by hybridization assay (HA) with the com- 
mercial ABBOTT immunoblot test or by polymerase 
chain reaction (PCR) were obtained at baseline, at the 
end of steroid withdrawal, at the end of treatment, and 
at two months post-treatment. PCR was done at the 
Royal Alfred Hospital, Sydney, Australia using Digene 
HBV-DNA kit. Alanine transferase (ALT) and aspartate 
transferase (AST) were done monthly. Serum bilirubin, 
serum albumin, alkaline phosphatase, prothrombin time, 
fasting blood glucose, urea, creatinine, sodium, and 
potassium were done at baseline. 
The primary outcome variables were clearance of 
HBeAg and seroconversion to positive anti-HBe. The 
secondary outcome variables included normalization of 
ALT, loss of serum HBV-DNA, loss of HBsAg, and 
seroconversion to positive antiHBs. To assess for safety, 
drug toxicity was scored by using symptoms and mean 
values of hemoglobin; neutrophil and platelet count 
were determined monthly. 
All statistical tests were done with the Statistical 
Package for the Social Sciences for Windows (SPSS for 
Windows Version 7.5). In-group analysis of parametric 
data was performed using paired t-test whereas between- 
group comparison was carried out with unpaired t-test. 
Analysis of covariance adjusted for baseline value was 
applied to the data to compare laboratory results of the 
two groups. Fisher’s exact probability test was used to 
compare the primary and secondary outcome variables. 
The clinical trial was approved by the International 
Review Board of the Makati Medical Centre-Tropical 
Disease Foundation in accordance with the Helsinki 
Declaration. 
RESULTS 
Study population 
Of 459 patients with chronic HBV infection screened, 
100 (22%) had replicative disease and 44 (10%) had 
evidence of necroinflammatory disease. Thirty-six 
patients were enrolled in the study. Enrollment was 
terminated after a 5-year patient accrual, since most 
patients screened had no replicative disease or evidence 
of necroinflammatory liver involvement. 
Table 2. Efficacy of IFN-a-n1 [INS] vs placebo: primary analysis (r-r=14 vs n=16) and intent to treat analysis (n=17 vs n=19) based on 
primary and secondary outcome variables 
Outcome variables 
Primary analysis Intent to treat analysis 
IFN-cx-n I [INS] Placebo IFN-cc-n1 [INS] Placebo 
N=14 N=76 N=17 N=19 
f%) W) P value (%) (W P value 
Primary: 
Clearance of H8eAg 
Seroconversion to anti-HBe 
Secondary: 
Normalization of ALT 
Clearance of HBV-DNA* 
Clearance of HBsAg 
Seroconversion to anti-HBS 
7 (50) 0 0.002 7 (42.2) 0 0.002 
6 (42.9) 0 0.005 6 (35.3) 0 0.006 
8 (57.1) 5 (31.3) 0.15 7 (41.2) 4 (41.2) 0.34 
7 (50) 6 37.5) 0.49 7 (41.2) 7 (36.8) 0.94 
0 0 1.0 0 0 1.0 
0 0 1.0 0 0 1.0 
*Loss of serum HBV-DNA at any time during the period of observation 
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Figure 1. Mean alanine aminotransferase (ALT) in various phases of treatment course among patients on IFN-a-n1 [INS] (n=14), and 
placebo (n=16).There is an evident flare in the mean ALT level in patient on IFN-ol-nl [INS] with normalization of ALT level from 
among the responders, which were not observed in those with placebo. 
Seventeen patients were randomized to IFN-a-n1 
[INS] and 19 to placebo (Table 1) There were three 
patients in each treatment arm who could not be 
evaluated; three on IFN-a-n1 [INS] and two on placebo 
were lost to follow up, and one on placebo had early 
withdrawal and was switched to IFN-a-n1 [INS] for 
HBV-related glomerulonephritis. Except for this patient, 
all were asymptomatic. The proportion of females in 
each treatment group, the mean age, baseline mean 
serum HBV-DNA, ALT, and AST levels showed no 
statistically significant differences between the two 
treatment groups at randomization, or between those 
who could and could not be evaluated in each treatment 
arm, or between those who could be evaluated in both 
treatment arms. 
Virological response 
Clearance of HBeAg was noted in seven (50.0%) 
patients on IFN-a-n1 [INS] compared to none on 
placebo (P=O.O02 by Fishers exact test) (Table 2). Six 
(42.2%) of those who cleared HBeAg on IFN-a-n1 
[INS] had seroconversion to positive anti-HBe while 
none on placebo did (P=O.O5). This had a power of 0.9, 
at a 95% confidence level, to detect a statistically signifi- 
cant difference. 
Clearance of serum HBV-DNA at some point 
during the observation period in seven (50.0%) on IFN- 
a-n1 [INS] (including five of those who cleared HBeAg 
and seroconverted to antiHBe) was not significantly 
different compared to six (37.5 %) on placebo. None had 
clearance of HBsAg or seroconversion to positive anti- 
HBs. 
Normalization of ALT in eight (57.1%) on IFN-a- 
nl [INS] compared to five (31.3%) on placebo was not 
significantly different. The mean ALT of those on 
placebo remained generally the same throughout the 
observation course (Figure 1). In contrast, a flare of the 
ALT mean levels was seen in the patients on IFN-a-n1 
[INS] after steroid withdrawal and at one month after 
the start of IFN-a-n1 [INS] therapy. 
Intent to treat analysis 
Clearance of HBeAg in seven (41.2%) and sero- 
conversion to positive anti-HBe in six (35.3%) in the 
treatment arm were significantly greater than those in 
the placebo arm on intent to treat analysis (P=O.O02 and 
P=O.O06, respectively).The secondary outcome variables 
were not different in the two groups. 
Safety assessments 
Except for one patient who developed a drug-induced 
hypersensitivity skin reaction, no adverse reaction 
necessitating drug discontinuation or dosage adjustment 
was observed. Figure 2 shows the: a) mean hemoglobin 
levels and b) white blood cell count in patients on either 
treatment arm at various points of their treatment 
course. No statistically significant difference of these 
parameters was noted in the two groups. 
DISCUSSION 
The Philippines is a mesoendemic area for HBV 
infection with HbsAg-positive prevalence of 12%.9 
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Transmission is primarily vertical and most infections 
are therefore acquired early in life. While most patients 
with HBV infection progress to chronicity, however, 
only 22% have replicative disease, and only 10% had 
evidence of necroinflammatory liver disease with low 
levels of aminotransferase elevation as shown in those 
patients screened in this study. Treatment is therefore 
indicated only in a minority of patients. 
The response rate with oromucosal low-dose IFN- 
a-n1 [INS] in these Filipino patients studied was 50.0% 
and is similar to those reported with the use of parenteral 
interferon among Caucasian as well as Asian patients.2-5 
Because post-treatment follow up in this study was 
limited to only two months after end of therapy, the 
delayed long-term beneficial effects of IFN-a was not 
ascertained. The encouraging results reported herein, 
however, should be interpreted with caution, as definite 
conclusions cannot be drawn from this small number of 
patients studied. 
The evident flare in ALT levels noted at steroid 
withdrawal and one month after start of IFN-a-n1 [INS] 
is similar to what has been observed with parenteral 
IFN-a and has previously been reported with oro- 
mucosal IFN-a lozenges in patients with chronic viral 
hepatitis B infection.* The subsequent decline in the 
mean levels of ALT in those on IFN-a-n1 [INS] suggests 
an amelioration of the necroinflamatory liver disease. 
This was more evident in those with HBeAg clearance, 
all of whom showed a return to normal ALT values that 
was sustained up to two months post-treatment. 
Other than one case of drug-induced perivascular 
dermatitis, signs and symptoms of toxicity were absent. 
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Figure 2. a) Mean hemoglobin levels and b) white blood cell at 
various phases of the treatment course in patients on IFN-a-n1 
(INS) (n=17) or placebo (n=19).The mean values of 
hemoglobin, white blood cells showed no significant 
difference among patient on IFN-a-n1 (INS) compared to those 
on placebo. 
This is consistent with earlier reports in animal models 
in which antitumor and antiviral effects of IFN-a-n1 
[INS] were noted without the associated signs of myelo- 
suppression.7,10 From these studies, Tovey and co- 
workers postulated a novel mechanism of action that 
is different from that of parenteral interferon. They 
proposed that oromucosal INF-a binds to high affinity 
cell surface receptors present in the lymphoid tissues 
in the oral cavity leading to the phosphorylation and 
activation of signal transducers and activators of 
transcription (STAT) proteins. This binding, they claim, 
modulates the transcription of interferon-sensitive genes 
resulting in immune stimulation mediated by the neo- 
synthesis of a novel soluble factor in conjunction with 
CD4+ T lymphocytes with a Th 1 phenotype.rO,rl The 
enhanced Th 1 cell-mediated immunity is hypothesized 
to be responsible for the biological and clinical activities 
of IFN-a-n1 [INS]. Alternatively, it has also been 
proposed that the IFN-alpha receptor binding may 
activate specific cell populations; presumably the intra- 
epithelial yS T cells, which enter the circulation to 
mediate the antitumor and antiviral effects of bro- 
mucosal IFNa.ll 
The absence of adverse drug effects and the lower 
cost of the drug would make it a more cost effective 
alternative to parenteral interferon. Excluding the cost 
of steroid priming, the cost incurred with IFN-a-n1 
[INS] treatment for an eight-month course based on 
year 2000 price of US$5.24 per tablet in the Philippines 
is US$1174.63 compared to US$2127-US$3190 cost 
incurred for parenteral interferon given five million IU 
thrice weekly for 16-24 weeks based on a corresponding 
unit cost of US$44.31 for the parenteral formulation. 
This cost saving would be an important consideration 
particularly for countries with limited resources like the 
Philippines, where HBV infection continues to be a 
significant public health problem. The therapeutic 
benefits of oromucosal IFN-a-n1 [INS] therapy need to 
be confirmed in a large scale study before definite 
recommendations for its use in chronic HBV infection 
can be made. 
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